MedTrace Logo

Evolocumab Versus LDL Apheresis in Patients With Hypercholesterolemia

NCT03429998 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2018-02-12

No results posted yet for this study

Summary

An open-label, prospective phase III study to compare the efficacy and safety of administering evolocumab versus treatment with LDLapheresis in patients with familial hypercholesterolemia and high cardiovascular risk.

Conditions

Interventions

DRUG

evolocumab

evolocumab 140 mg/biweekly

DRUG

evolocumab and LDL apheresis

evolocumab 140 mg/biweekly LDL-apheresis monthly

PROCEDURE

LDL apheresis

LDL apheresis biweekly

Sponsors & Collaborators

  • Hospital General Universitario Gregorio Marañon

    lead OTHER

Principal Investigators

  • Marian Goicoechea, MD, PhD · Hospital General Universitario Gregorio Marañon

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-01
Primary Completion
2018-01-28
Completion
2018-01-28

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03429998 on ClinicalTrials.gov